Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk

As Viatris Discloses ‘Challenging’ Orencia Biosimilar Is Part Of Pipeline Again

Executive Summary

Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.

You may also be interested in...



Biocon Closes $3bn Deal For Viatris Biosimilars

Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.

Viatris Tipped To Knock Out Crucial Eylea Dosing Patents In US

A senior analyst for a major investment bank has listened to oral arguments in Viatris’ legal tussle vs. Regeneron over two key US dosing patents shielding the originator’s Eylea (aflibercept) blockbuster.

Alvotech Kicks Off Trials For Eylea Biosimilar

Alvotech has announced the start of clinical trials for its AVT06 proposed aflibercept biosimilar rival to Eylea, joining a host of other developers pursuing the same target.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel